Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 2/20 | 0.54 |
| ▸ | DAO | P14920 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26670773 | 0.82 | GAA (0.46) | HSD17B10HPGDALDH1A1KDM4EMAPT | |
| SCHEMBL3551666 | 0.80 | KDM4E (0.50) | HSD17B10HPGDALDH1A1DAOKDM4E | |
| SCHEMBL24896451 | 0.80 | IMPDH2 (0.40) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL6514088 | 0.79 | KDM4E (0.54) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL2450985 | 0.78 | HSD17B10 (0.53) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL17136028 | 0.78 | HSD17B10 (0.64) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL2004648 | 0.76 | KDM4E (0.63) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL11035155 | 0.76 | HSD17B10 (0.62) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL24896431 | 0.76 | SMYD3 (0.55) | HSD17B10HPGDKDM4EMAPTNSD2 | |
| SCHEMBL3632164 | 0.75 | HSD17B10 (0.60) | HSD17B10HPGDALDH1A1MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370207-B1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4587433-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Takeda Pharmaceutical Company Limited (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250026719-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| US-20240368137-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12012398-B2 | Bicyclic compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4370207-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4367107-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024059087-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| CN-117616019-A | Novel compounds as PCSK9 inhibitors | 晟科药业（江苏）有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230122967-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023280155-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023280155-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-01-12 | — | — | WO | disclosed |
| WO-2021143762-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2021-07-22 | — | — | WO | disclosed |
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004101767-A2 | CBI ANALOGUES OF THE DUOCARMYCINS AND CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-0234540-B1 | HEAT-SENSITIVE RECORDING MATERIAL | KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) | 1991-10-16 | — | — | EP | disclosed |
| US-4731353-A | METAL SALT OF INDOLE-2-CARBOXYLIC ACID COLOR DEVELOPER | KANZAKI PAPER MANUFACTURING COMPANY, LIMITED (JP) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | HSD17B10 73/4885HPGD 1466/4885ALDH1A1 2558/4885 |
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | CCNI, SP1, DCK | HSD17B10 4567/4885HPGD 4309/4885ALDH1A1 4597/4885 |
| US-20250026719-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | HSD17B10 247/4885HPGD 2236/4885ALDH1A1 3394/4885 |
| US-20240368137-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | HSD17B10 73/4885HPGD 1466/4885ALDH1A1 2558/4885 |
| US-12012398-B2 | Bicyclic compounds as androgen receptor modulators | AR, FSHR, NCOA3 | HSD17B10 83/4885HPGD 1635/4885ALDH1A1 2865/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | HSD17B10 700/4885HPGD 3962/4885ALDH1A1 876/4885 |
| US-20230122967-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | HSD17B10 247/4885HPGD 2236/4885ALDH1A1 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.